AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12875349
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Diamicron)
Trial: 10647194
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg at 22.00)
Trial: 8690104
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (50 mg daily on days 1 to 10 of the menstrual cycle) and estrogen (35 microg ethinyl E2 daily on days 1 to 21)
Trial: 6147051
Drug: Oxmetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxmetidine 200 mg
Trial: 31950597
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with a dose of 66 Gy in 33 fractions from parallel opposed lateral beams.
Trial: 28435464
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks
Trial: 25801872
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment (SBP <180 mm Hg)
Trial: 27550722
Drug: Combined preoperative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preoperative oral antibiotics (metronidazole and kanamycin) and perioperative intravenous antibiotics (cefmetazole) (oral/IV group)
Trial: 27550722
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (cefmetazole) alone (IV-only group)
Trial: 23665990
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment (omeprazole 20 mg/12 h, amoxicillin 1 g/12 h, clarithromycin 500 mg/12 h, metronidazole 500 mg/12 h for 10 days)
Trial: 23665990
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (omeprazole 20 mg/12 h and amoxicillin 1 g/12 h for 5 days, followed by omeprazole 20 mg/12 h, clarithromycin 500 mg/12 h, and metronidazole 500 mg/12 h for 5 days)
Trial: 16868694
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg b.i.d starting the day of surgery, discontinued 15 days after catheter removal.
Trial: 3728926
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg + intravenous naloxone 2 mg for 12 hours
Trial: 3511767
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg
Trial: 8034388
Drug: Intravenous naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous naloxone
Trial: 3728926
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 mg morphine intramuscularly + 20 ml epidural saline)
Trial: 29512481
Drug: DPIV 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPIV 4 μg with alum
Trial: 29512481
Drug: DPIV 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPIV 1 μg + AS03B
Trial: 15361722
Drug: Amoxicillin/clavulanate (45/6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (45/6.4 mg/kg divided twice daily)
Trial: 7518981
Drug: Terazosin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (10 mg once daily)
Trial: 23121256
Drug: Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jessner's solution peels
Trial: 2211568
Drug: Buspirone 5
RxNorm normalized name: busPIRone 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 5 mg t.i.d.
Trial: 24315572
Drug: Polysomnographic sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysomnographic sleep during inpatient treatment
Trial: 18506008
Drug: Ambrisentan monotherapy
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ambrisentan monotherapy
Trial: 18388356
Drug: Acetazolamide (Acz)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (Acz) 250 mg/d for 12 weeks
Trial: 15807672
Drug: Doxycycline twice
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline twice a day for the first month, once a day for the second and third months.
Trial: 12038039
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei and L. acidophilus strains CERELA (1.5 g each)
Trial: 10217552
Drug: Contingent voucher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingent voucher incentives (n = 19) for each consecutive naltrexone dose ingested
Trial: 10158377
Drug: Atherectomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atherectomy treatment of bifurcation lesions
Trial: 10158377
Drug: Angioplasty treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angioplasty treatment of bifurcation lesions
Trial: 2526999
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (220 mg Zn sulfate orally)
Trial: 106965
Drug: standard prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard prophylaxis administered to 9 patients
Trial: 21855592
Drug: 9 μg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 μg ID-TIV
Trial: 21855592
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg ID-TIV
Trial: 21855592
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg IM VA-TIV
Trial: 9209168
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g soy protein
Trial: 9209168
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g soy protein
Trial: 9209168
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g soy protein
Trial: 16353603
Drug: Etiocholanedione (ED),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiocholanedione (ED), 4 gm daily
Trial: 24942380
Drug: Phototherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phototherapy with 30 J dose
Trial: 16396746
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment modalities
Trial: 1486224
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (MCF: mitoxantrone, cyclophosphamide, 5‐fluorouracil)
Trial: 9462526
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) at therapeutic concentrations
Trial: 9462526
Drug: Enoxaparin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.25 U/mL)
Trial: 9462526
Drug: Argatroban (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (1 ng/mL)
Trial: 7622771
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg b.i.d.) + Coamoxiclav (1 g b.i.d.) for 3 weeks
Trial: 7622771
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg b.i.d.) + Coamoxiclav (1 g b.i.d.) for 6 weeks
Trial: 22374183
Drug: Troponin I
RxNorm normalized name: Troponin I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin I ≥0.040 μg/L (n=497)
Trial: 22374183
Drug: NT‐proBNP <387
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP <387 ng/L
Trial: 22374183
Drug: NT‐proBNP >1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP >1402 ng/L
Trial: 10485531
Drug: Irrigating balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigating balanced salt solution supplemented with vancomycin (10 microg/ml)
Trial: 1657505
Drug: L‐[1‐13C]leucine continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐[1‐13C]leucine continuous infusion
Trial: 1657505
Drug: Flooding amount
RxNorm normalized name: Adenosine 0.0006 g in 1.5 mL TOPICAL CREAM [CAVIALL Aqua Flood Water]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flooding amount of L‐[1‐13C]leucine
Trial: 1446756
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol
Trial: 12519036
Drug: Ibuprofen isobutanolammonium
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen isobutanolammonium
Trial: 1819034
Drug: EAA in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EAA in a routine dose
Trial: 1819034
Drug: EAA in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EAA in a much smaller dosage
Trial: 25994567
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA therapy
Trial: 15808754
Drug: Hyperglycemia (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (defined as glucose > or =7.8 mmol/l or 140 mg/dl)
Trial: 15808754
Drug: Non-hyperglycemic patients
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hyperglycemic patients (glucose < 7.8 mmol/l)
Trial: 20125070
Drug: Hyperbaric levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric levobupivacaine (13.5 mg, intrathecally in 3 mL)
Trial: 20125070
Drug: Isobaric levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric levobupivacaine (13.5 mg, intrathecally in 3 mL)
Trial: 8673823
Drug: Ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin treatment (at least three doses)
Trial: 8673823
Drug: Ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin treatment (annual treatment interval)
Trial: 6416853
Drug: Oral 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25-hydroxyvitamin D3 treatment
Trial: 6416853
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in absorption on treatment
Trial: 30808623
Drug: COBRA (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA (combination of sulfasalazine, low-dose methotrexate, and initially high, step-down prednisolone)
Trial: 27731538
Drug: Methotrexate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (50 mg/m2)
Trial: 15346750
Drug: Immediate provisional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate provisional restoration of Osseotite implants
Trial: 11334210
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (CT)
Trial: 373088
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg levamisole tablets
Trial: 21618678
Drug: Anticoagulants (enoxaparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (enoxaparin, unfractionated heparin, fondaparinux, bivalirudin)
Trial: 11443205
Drug: Pegvisomant (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (1 mg/kg)
Trial: 9522024
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (CH) 500 mg as drinking solution
Trial: 9522024
Drug: Chloraldurat rot
RxNorm normalized name: Sheep-rot Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloraldurat rot (CR) one capsule
Trial: 30877049
Drug: Attention Bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Bias Modification Treatment (ABMT)
Trial: 22018679
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg BID)
Trial: 23850610
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) administration of LIPO-4 vaccine
Trial: 19884541
Drug: Triple intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple intrathecal therapy (methotrexate with cytarabine and hydrocortisone)
Trial: 11381675
Drug: E5880 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5880 (300 micrograms or 1200 micrograms twice daily) administered intravenously for 14 days
Trial: 8094828
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (IVMP) 500 mg daily for 5 days
Trial: 3531936
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg pure porcine relaxin
Trial: 27793204
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenously administered ferric carboxymaltose
Trial: 24142084
Drug: Conventional cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cognitive therapy (CCT)
Trial: 15766302
Drug: Once-weekly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly oral morphine
Trial: 19926048
Drug: 0.50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg/kg enoxaparin
Trial: 19926048
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg enoxaparin
Trial: 19926048
Drug: UFH (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH (unfractionated heparin)
Trial: 14657039
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (8 g carbohydrate, 10 g protein, 3 g fat)
Trial: 14657039
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 g carbohydrate, 0 g protein, 0 g fat)
Trial: 3671250
Drug: nifedipine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (up to 60 mg/day)
Trial: 3671250
Drug: prazosin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prazosin (up to 20 mg/day)
Trial: 3671250
Drug: hydralazine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydralazine (up to 200 mg/day)
Trial: 20118387
Drug: Prescription omega-3-acid
RxNorm normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3-acid ethyl esters plus atorvastatin (20 mg/d)
Trial: 20118387
Drug: Prescription omega-3-acid
RxNorm normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3-acid ethyl esters plus atorvastatin (40 mg/d)
Trial: 20118387
Drug: Prescription omega-3-acid
RxNorm normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3-acid ethyl esters plus atorvastatin
Trial: 22108152
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus atorvastatin
Trial: 18807572
Drug: Early placement
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early placement of single-tooth implants (average 10 days after extraction)
Trial: 18807572
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of single-tooth implants (3 months after extraction)
Trial: 18807572
Drug: Early placement
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early placement of single-tooth implants
Trial: 18807572
Drug: Delayed placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed placement of single-tooth implants
Trial: 18807572
Drug: Both early
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both early and delayed placement of single-tooth implants
Trial: 11323340
Drug: Control (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (intranasal saline)
Trial: 7898092
Drug: Cilazapril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (ACE inhibitor)
Trial: 25514667
Drug: ICP-targeted treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-targeted treatment
Trial: 1571119
Drug: Systemic antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antimicrobial treatment in children with inflamed middle ear mucosa or positive cultures
Trial: 4091238
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg methohexital/kg BW
Trial: 4091238
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methohexital/kg BW
Trial: 4091238
Drug: Methohexital plasma
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital plasma levels > 22 micrograms/ml
Trial: 24768678
Drug: 1760 mcg
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1760 mcg daily fluticasone propionate (FP) for 3 months
Trial: 24768678
Drug: 880 mcg
RxNorm normalized name: mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 880 mcg daily fluticasone propionate (FP) after initial CR
Trial: 24768678
Drug: 1760 mcg
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1760 mcg daily fluticasone propionate (FP)
Trial: 14622077
Drug: 16-week treatments
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16-week treatments for depression
Trial: 8737129
Drug: Sparfloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (200 mg loading dose followed by 100 mg once daily)
Trial: 8737129
Drug: Amoxycillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanic acid (500 mg/125 mg tds)
Trial: 26345362
Drug: Three sessions
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three sessions of breathing training (hour-long sessions at weekly intervals)
Trial: 19153079
Drug: 0.5 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 h infusion of 0.5 g of imipenem every 6 h for 24 h
Trial: 19153079
Drug: 2 h
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h infusion of 0.5 g of imipenem every 6 h for 24 h
Trial: 19153079
Drug: 2 h
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h infusion of 1 g of imipenem every 6 h for 24 h
Trial: 8615360
Drug: RRR-alpha-tocopherol supplementation
RxNorm normalized name: RRR-alpha-tocopheryl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopherol supplementation (1632 mg or 1200 IU/d) for 8 weeks
Trial: 21907540
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (GCBT)
Trial: 30189840
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid
Trial: 12527979
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of glucose ingested 45 min prior to exercise
Trial: 10656432
Drug: Melphalan 20
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 20 mg/m2 (n = 5)
Trial: 10656432
Drug: Melphalan 30
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 30 mg/m2 (n = 7)
Trial: 10656432
Drug: Melphalan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan (all doses)
Trial: 1993621
Drug: Revised criteria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revised criteria for unacceptable overall treatment including prolonged elapsed treatment days
Trial: 30934066
Drug: Rituximab (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (500 mg/m2, 2 infusions 2 weeks apart, followed by 4 maintenance infusions of 500 mg at 3, 6, 9, and 12 months)
Trial: 17425756
Drug: Prednisone dosage
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone dosage higher than 20 mg/d
Trial: 17425756
Drug: Steroids administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroids administration
Trial: 17425756
Drug: Steroids therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids therapy
Trial: 12471401
Drug: Aerosolized measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized measles vaccine (Edmonston-Zagreb)
Trial: 12471401
Drug: Aerosolized measles-rubella
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized measles-rubella vaccine (Edmonston-Zagreb with RA27/3)